Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AbundRX vs Medsol RX

AbundRX
Graded #181

Higher grade

vs+5.599999999999994
Medsol RX
Graded #306

Lower grade

The verdict

AbundRX takes it — 66.6/100 to 61/100.

AbundRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. AbundRX (Abundant Wellness) is an online medical weight-care platform connecting patients with licensed clinicians for compounded GLP-1 treatment.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAbundRX +22
67
45
Dose & formulationEven
64
64
Clinical oversightEven
79
79
Labs & monitoringEven
53
53
FulfillmentMedsol RX +9
74
83
Contract termsAbundRX +14
55
41
AbundRX · left barMedsol RX · right bar

The numbers

MetricAbundRXMedsol RX
WeighScore66.6/10061/100
GradeCC
Scorecard rank#181#306
Semaglutide$179/mo (compounded)$209/mo (compounded)
Tirzepatide$279/mo (compounded)$250/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AbundRX

Graded #181 · C

Strengths

  • Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
  • Fast, free shipping and a simple few-minute online health assessment
  • Provider-guided care connecting patients with licensed US clinicians
  • Publishes Terms, Privacy, and Refund policies

Where it loses points

  • Claims LegitScript certification in text but displays no verifiable seal or listing
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Compounding pharmacy not named; no HIPAA notice found; state availability not published
  • Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Medsol RX

Graded #306 · C

Strengths

  • Compounded semaglutide from $209/mo (12-mo plan) and tirzepatide from ~$250/mo; HSA/FSA eligible with Klarna financing
  • Every plan bundles the medication, a dedicated care coach, custom treatment plan, medical oversight, and free shipping
  • Board-certified clinicians via OpenLoop; same-day approvals; ships nationwide
  • Month-to-month option ($199 first month) with no long-term commitment, plus microdosing and wellness add-ons

Where it loses points

  • Doesn't name its compounding pharmacy (generic 'certified U.S. pharmacies')
  • No legal entity name published on the site
  • Tirzepatide pricing is given as a range ($250-$1,400/mo), not a fixed rate
  • Compounded GLP-1s are not FDA-approved (the site discloses this)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard